Efficacy News and Research

RSS

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

In a recent study under consideration at Nature Portfolio Journal and posted to the Research Square* preprint server, researchers characterized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-specific cluster of differentiation 8 (CD8+) T cell responses.

12 Apr 2022

New COVID-19 vaccine induces T-cell immune responses in most patients with B-cell deficiencies

CoVac-1, a new vaccine against SARS-CoV-2, induced T-cell immune responses in 93 percent of patients with B-cell deficiencies, including many patients with leukemia and lymphoma, according to results presented at the AACR Annual Meeting 2022, held April 8-13.

12 Apr 2022

Parallel approach to vaccine trials can lead to faster and more accurate assessment

Some of Rutgers' top health researchers are calling for a change in our approach to developing COVID-19 vaccines, and vaccines to fight future pandemics, to incorporate both conventional and challenge trails.

12 Apr 2022

Aprotinin could inhibit virus replications by preventing SARS-CoV-2 entry into host cells

A clinical study from Spain recently confirmed laboratory experiments made by researchers of Goethe University Frankfurt and University of Kent who showed that the protease inhibitor aprotinin prevented cells to be infected by SARS-CoV2.

12 Apr 2022

Decoy nanoparticles could provide a quick, effective treatment for COVID-19

They might look like cells and act like cells. But a new potential COVID-19 treatment is actually a cleverly disguised trickster, which attracts viruses and binds them, rendering them inactive.

12 Apr 2022

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

In a new study, researchers quantified the serological responses following the third dose of mRNA-based COVID-19 vaccines in patients with hematological malignancies.

12 Apr 2022

Early COVID-19 reinfections possible within 60 days of initial infection

Researchers reported that COVID-19 reinfections could occur within 60 days of the initial infection.

12 Apr 2022

Study finds efficacy of SARS-CoV-2 vaccines reported in Phase 3 trials declines as pandemic prevalence at trial sites increases

A recent study published in PLoS ONE assessed the association of the prevalence of the COVID-19 pandemic with vaccine efficacy.

12 Apr 2022

Exploring vaccine effectiveness against SARS-CoV-2 Omicron and Delta variants in adolescents

A new study assessed the effectiveness of the BNT162b2 SARS-CoV-2 vaccine against Delta and Omicron variants in adolescents.

12 Apr 2022

Scientists find critical role for Hippo signaling pathway in COVID-19 pathogenesis

A recent article posted to the bioRxiv* preprint server illustrated that the activation of the Hippo signaling pathway upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection aids the host antiviral response.

11 Apr 2022

Study identifies several therapeutically effective drugs for bladder cancer

Hundreds of chemical compounds were screened on cell cultures representing different stages and subtypes of bladder cancer and several promising agents with inhibitory (growth-inhibiting) effects were identified.

11 Apr 2022

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers - ATR inhibitor elimusertib and PARP inhibitor AZD5305 - are safe and clinically beneficial in treating patients with advanced solid tumors.

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Efficacy News and Research

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

New COVID-19 vaccine induces T-cell immune responses in most patients with B-cell deficiencies

Parallel approach to vaccine trials can lead to faster and more accurate assessment

Aprotinin could inhibit virus replications by preventing SARS-CoV-2 entry into host cells

Decoy nanoparticles could provide a quick, effective treatment for COVID-19

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

Early COVID-19 reinfections possible within 60 days of initial infection

Study finds efficacy of SARS-CoV-2 vaccines reported in Phase 3 trials declines as pandemic prevalence at trial sites increases

Exploring vaccine effectiveness against SARS-CoV-2 Omicron and Delta variants in adolescents

Scientists find critical role for Hippo signaling pathway in COVID-19 pathogenesis

Study identifies several therapeutically effective drugs for bladder cancer

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

New study reveals oral opaganib's potent in vitro activity against Omicron

Nanocell COVID-19 vaccine elicits potent neutralizing response

COVID-19 vaccines and reports of menstrual disorders

MU researchers receive grant to increase confidence about COVID-19 vaccine among nurses

Magic mushroom compound helps to 'open up' depressed people's brains after use

New instrument will help Columbia scientists to study heavy ion radiation therapy

Safety profile of colchicine in COVID-19 patients

Monitoring medication adherence for TB treatment in Africa using AI

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News